Apolipoprotein A-IV concentrations and clinical outcomes in a large chronic kidney disease cohort: Results from the GCKD study.
all-cause mortality
apolipoprotein A-IV
cardiovascular disease
heart failure
high risk population
prospective study
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
pubmed:
17
12
2021
medline:
15
4
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) represents a chronic proinflammatory state and is associated with very high cardiovascular risk. Apolipoprotein A-IV (apoA-IV) has antiatherogenic, antioxidative, anti-inflammatory and antithrombotic properties and levels increase significantly during the course of CKD. We aimed to investigate the association between apoA-IV and all-cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease study. This was a prospective cohort study including 5141 Caucasian patients with available apoA-IV measurements and CKD. The majority of the patients had an estimated glomerular filtration rate (eGFR) of 30-60 ml/min/1.73m Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dl. Patients in the highest apoA-IV quartile had the lowest high-sensitivity C-reactive protein values despite the highest prevalence of diabetes, albuminuria and the lowest eGFR. Each 10 mg/dl higher apoA-IV translated into lower odds of prevalent cardiovascular disease (1289 cases, odds ratio = 0.80, 95% confidence interval [CI] 0.72-0.86, p = 0.0000003). During follow-up, each 10 mg/dl higher apoA-IV was significantly associated with a lower risk for all-cause mortality (600 cases, hazard ratio [HR] = 0.81, 95% CI 0.73-0.89, p = 0.00004), incident major adverse cardiovascular events (506 cases, HR = 0.88, 95% CI 0.79-0.99, p = 0.03) and death or hospitalizations due to heart failure (346 cases, HR = 0.84, 95% CI 0.73-0.96, p = 0.01). These data support a link between elevated apoA-IV concentrations and reduced inflammation in moderate CKD. ApoA-IV appears to be an independent risk marker for reduced all-cause mortality, cardiovascular events and heart failure in a large cohort of patients with CKD.
Sections du résumé
BACKGROUND
Chronic kidney disease (CKD) represents a chronic proinflammatory state and is associated with very high cardiovascular risk. Apolipoprotein A-IV (apoA-IV) has antiatherogenic, antioxidative, anti-inflammatory and antithrombotic properties and levels increase significantly during the course of CKD.
OBJECTIVES
We aimed to investigate the association between apoA-IV and all-cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease study.
METHODS
This was a prospective cohort study including 5141 Caucasian patients with available apoA-IV measurements and CKD. The majority of the patients had an estimated glomerular filtration rate (eGFR) of 30-60 ml/min/1.73m
RESULTS
Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dl. Patients in the highest apoA-IV quartile had the lowest high-sensitivity C-reactive protein values despite the highest prevalence of diabetes, albuminuria and the lowest eGFR. Each 10 mg/dl higher apoA-IV translated into lower odds of prevalent cardiovascular disease (1289 cases, odds ratio = 0.80, 95% confidence interval [CI] 0.72-0.86, p = 0.0000003). During follow-up, each 10 mg/dl higher apoA-IV was significantly associated with a lower risk for all-cause mortality (600 cases, hazard ratio [HR] = 0.81, 95% CI 0.73-0.89, p = 0.00004), incident major adverse cardiovascular events (506 cases, HR = 0.88, 95% CI 0.79-0.99, p = 0.03) and death or hospitalizations due to heart failure (346 cases, HR = 0.84, 95% CI 0.73-0.96, p = 0.01).
CONCLUSIONS
These data support a link between elevated apoA-IV concentrations and reduced inflammation in moderate CKD. ApoA-IV appears to be an independent risk marker for reduced all-cause mortality, cardiovascular events and heart failure in a large cohort of patients with CKD.
Identifiants
pubmed: 34914850
doi: 10.1111/joim.13437
pmc: PMC9305919
doi:
Substances chimiques
Apolipoproteins A
0
apolipoprotein A-IV
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-636Informations de copyright
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Références
J Clin Invest. 2004 Jul;114(2):260-9
pubmed: 15254593
Lancet. 2013 Jul 27;382(9889):339-52
pubmed: 23727170
Am J Pathol. 2013 May;182(5):1474-81
pubmed: 23608224
J Am Coll Cardiol. 2010 Mar 23;55(12):1266-1273
pubmed: 20206456
J Intern Med. 2021 Oct;290(4):910-921
pubmed: 33998741
J Am Coll Cardiol. 2017 Oct 17;70(16):2006-2019
pubmed: 29025558
Chin Med J (Engl). 2001 Mar;114(3):275-9
pubmed: 11780313
Science. 1996 Aug 16;273(5277):966-8
pubmed: 8688083
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9641-6
pubmed: 22619326
Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G472-81
pubmed: 25591862
J Lipid Res. 2006 Sep;47(9):2071-9
pubmed: 16788210
PLoS One. 2015 Apr 24;10(4):e0124772
pubmed: 25909952
Kidney Int. 2016 Apr;89(4):747-9
pubmed: 26994572
Nephrol Dial Transplant. 2015 Mar;30(3):441-51
pubmed: 25271006
Kidney Int. 1999 May;55(5):1899-911
pubmed: 10231453
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):271-9
pubmed: 26668021
Nat Commun. 2018 Sep 6;9(1):3608
pubmed: 30190457
Clin J Am Soc Nephrol. 2011 Nov;6(11):2650-6
pubmed: 21903986
Kidney Int. 2020 Aug;98(2):488-497
pubmed: 32641227
Epidemiol Methods. 2014 Jan;2(1):95-115
pubmed: 25580377
N Engl J Med. 2008 Oct 30;359(18):1897-908
pubmed: 18971492
J Am Soc Nephrol. 1995 Jul;6(1):110-20
pubmed: 7579063
Nephrol Dial Transplant. 2019 Nov 1;34(11):1803-1805
pubmed: 31566230
Ther Apher Dial. 2010 Jun;14(3):341-8
pubmed: 20609189
J Biol Chem. 1990 May 15;265(14):7859-63
pubmed: 2159462
J Intern Med. 2015 Oct;278(4):410-23
pubmed: 26037138
J Am Soc Nephrol. 2007 Apr;18(4):1307-15
pubmed: 17344421
Atherosclerosis. 2020 Mar;297:146-148
pubmed: 32057405
Biochim Biophys Acta. 1986 Aug 14;878(1):7-13
pubmed: 3089295
Kidney Int Suppl. 2008 Dec;(111):S4-9
pubmed: 19034325
Nephrol Dial Transplant. 2004 Jul;19(7):1829-34
pubmed: 15128888
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
J Am Soc Nephrol. 2002 Feb;13(2):461-469
pubmed: 11805176
J Am Soc Nephrol. 2006 Feb;17(2):528-36
pubmed: 16382017
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):756-61
pubmed: 14751811
Eur Heart J. 2021 Jan 1;42(1):113-131
pubmed: 32176778
JAMA. 2004 Jan 28;291(4):451-9
pubmed: 14747502
Kidney Int. 2005 Sep;68(3):1130-6
pubmed: 16105043
J Clin Invest. 1997 Apr 15;99(8):1906-16
pubmed: 9109435
J Clin Invest. 1980 Apr;65(4):911-9
pubmed: 6987270
J Am Coll Cardiol. 2000 Sep;36(3):751-7
pubmed: 10987595
Circulation. 2021 Mar 16;143(11):1157-1172
pubmed: 33720773
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Lipid Res. 2015 Aug;56(8):1403-18
pubmed: 25640749
Curr Opin Lipidol. 2017 Feb;28(1):39-45
pubmed: 27870653
Eur J Biochem. 1979 Sep;99(2):333-43
pubmed: 115688
Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1399-411
pubmed: 24855059
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Clin Chim Acta. 1987 Aug 31;167(3):303-11
pubmed: 3621614
J Intern Med. 2012 Dec;272(6):592-600
pubmed: 22891946
J Intern Med. 2022 May;291(5):622-636
pubmed: 34914850
J Am Soc Nephrol. 2007 Jan;18(1):16-28
pubmed: 17167116
Kidney Int. 2019 Jun;95(6):1304-1317
pubmed: 31053387
J Lipid Res. 2003 Aug;44(8):1523-9
pubmed: 12777472
J Lipid Res. 1994 Jul;35(7):1318-28
pubmed: 7964193
Atherosclerosis. 2016 Aug;251:39-46
pubmed: 27240254